VPC-18005

Research use only, not for human use.

VPC-18005 is a luciferase inhibitor. VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain thereby disrupting the ERG binding to DNA.

VPC-18005 is a luciferase inhibitor. VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain thereby disrupting the ERG binding to DNA.(In Vitro):VPC-18005 (1 and 10 μM) produced a 20–30% decrease in the dissemination of cancer cells in zebrafsh. VPC-18005 (5 μM) inhibits pETS-luc reporter activity with IC50s of 3 and 6 μM in PNT1B-ERG and VCaP cells, respectively. VPC-18005 antagonizes the metastatic potential of ERG-expressing prostate cells and suppresses ERG reporter activity without exhibiting overt cytotoxicity. VPC-18005 inhibits migration and invasion of ERG-overexpressing cells in vitro.

VPC-18005 is found to inhibit pETS-luc reporter activity in PNT1B-ERG and VCaP cells with IC50 values of 3 and 6 μM, respectively.VPC-18005 could suppress ERG reporter activity without exhibiting overt cytotoxicity.VPC-18005 inhibits migration and invasion of ERG-overexpressing cells in vitro.VPC-18005 can antagonize the metastatic potential of ERG-expressing prostate cells.The exposure of larvae to 1 or 10 μM of VPC-18005 produced a 20–30% decrease in the dissemination of cancer cells in zebrafsh. Cell Viability AssayCell Line:PNT1B-Mock cells and PNT1B-ERG cells.Concentration:5 μM.Incubation Time:24 h.Result:Inhibited migration and invasion of prostate cell lines in vitro.

——

——

Others

Other Targets

——

——

——

2242480-48-2

319.38

C15H17N3O3S

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (195.69 mM)

N(/N=C\C1=CC=C(C(C)C)C=C1)=C\2/SC(CC(O)=O)C(=O)N2

——

(-20℃)

With Ice Pack

≥ 2 years